Use of archived specimens in evaluation of prognostic and predictive biomarkers (Q35007222)

5 August 2017

Use of archived specimens in evaluation of prognostic and predictive biomarkers (English)

1 reference

5 August 2017

0 references

Richard M Simon

1

1 reference

5 August 2017

Soonmyung Paik

series ordinal

2

1 reference

5 August 2017

Daniel F Hayes

series ordinal

3

1 reference

5 August 2017

language of work or name

English

0 references

publication date

8 October 2009

1 reference

Journal of the National Cancer Institute

5 August 2017

1 reference

5 August 2017

101

1 reference

5 August 2017

1446-1452

1 reference

5 August 2017

21

1 reference

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

5 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2782246

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2782246

The use of genomics in clinical trial design

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2782246

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2782246

Letting the genome out of the bottle--will we get our wish?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2782246

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2782246

Development and clinical indications of cetuximab.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2782246

ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2782246

Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2782246

Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2782246

Use of genomic signatures in therapeutics development in oncology and other diseases

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2782246

Roadmap for developing and validating therapeutically relevant genomic classifiers

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2782246

Clinical trial designs for predictive marker validation in cancer treatment trials

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2782246

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2782246

Reporting recommendations for tumor marker prognostic studies (REMARK).

8 July 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP335

Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP335

Sample size requirements and length of study for testing interaction in a 2 x k factorial design when time-to-failure is the outcome [corrected]

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP335

Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP335

The taxane limbo: how low can we go?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP335

Targeting EGFR in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP335

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP335

Recommendations for Improved Standardization of Immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP335

New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK

21 January 2018

1 reference

12 December 2020

TAILORx: trial assigning individualized options for treatment (Rx)

1 reference

12 December 2020

Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients

1 reference

12 December 2020

Rules of evidence for cancer molecular-marker discovery and validation

1 reference

12 December 2020

Designs and adaptive analysis plans for pivotal clinical trials of therapeutics and companion diagnostics

1 reference

12 December 2020

Estrogen receptor antibody incubation time and extent of immunoreactivity in invasive carcinoma of the breast: the importance of optimizing antibody avidity

1 reference

12 December 2020

Identifiers

DOI

10.1093/JNCI/DJP335

1 reference

5 August 2017

1 reference

5 August 2017

1 reference